Other anti-VEGF drugs are also being evaluated in the combined therapy with immunotherapy for HCC treatment (ClinicalTrials.gov number: NCT03170960 (Cabozantinib and Atezolizumab) and NCT03006926 (Lenvatinib and Pembrolizumab)). Here, VEGFA is linked to hepatocellular carcinoma.